2019 LMG Life Sciences research has officially begun!
March 22, 2019
Now accepting firm surveys and partner interviews
US
General Patent Litigation
Hatch-Waxman Patent Litigation (Branded)
| Hatch-Waxman Patent Litigation (Branded) — Highly recommended |
|---|
| Covington & Burling |
| Finnegan Henderson Farabow Garrett & Dunner |
| Fish & Richardson |
| Paul Hastings |
| Sidley Austin |
| Venable |
| Williams & Connolly |
| WilmerHale |
| Hatch-Waxman Patent Litigation (Branded) — Recommended |
|---|
| Arnold & Porter |
| Bartlit Beck |
| Dechert |
| Goodwin Procter |
| Jones Day |
| Kirkland & Ellis |
| Mayer Brown |
| Quinn Emanuel Urquhart & Sullivan |
| Lawyer | Section | Practice Area | Location |
|---|---|---|---|
| Dittmann, Eric | Intellectual Property | General Patent Litigation, Patent Strategy & Management, Hatch-Waxman Patent Litigation | New York City |
| Giampetruzzi, Gary | Non-IP Litigation & Enforcement | White-Collar/Govt. Investigations | New York City |
| Modi, Naveen | Intellectual Property | General Patent Litigation | Washington, D.C. |
| O'Malley, Joseph | Intellectual Property | Patent Strategy & Management, Hatch-Waxman Patent Litigation | New York City |
| Peterman, Chad J | Intellectual Property | Hatch-Waxman Patent Litigation | New York City |
| Ratliff II, Preston | Intellectual Property | Hatch-Waxman Patent Litigation | New York City |
| Wexler, Bruce M | Intellectual Property | Patent Strategy & Management, Hatch-Waxman Patent Litigation | New York City |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Intellectual Property
Paul Hastings
Paul Hastings has a booming presence in the life sciences IP space, evidenced by its top ranking in both general patent litigation and Hatch-Waxman disputes. In addition to its courtroom capabilities, the firm is also renowned for its strong post-grant group handling contentious proceedings at the Patent Office. This year the firm had significant activity representing pharmaceutical clients in noteworthy cases, prompting its recognition as the 2018 LMG Life Sciences Hatch-Waxman Litigation Firm of the Year on the branded side.
One peer says the Paul Hastings patent litigation team is able to provide "excellent service in the area," while another notes, "These are people I can tell unequivocally belong on the list." Bruce Wexler is one of the firm's IP litigation headliners and serves as chair of the life sciences group. He and Chad Peterman were recently involved in a complete trial victory for Orexigen against opponent Actavis which sought generic entry for the client's branded weight loss drug Contrave.
Along with Wexler, Eric Dittmann and Patent Office group leader Naveen Modi led the successful challenge of a key patent related to blockbuster Humira portfolio. The three partners represented Boehringer Ingelheim in two IPRs before the Patent Trial and Appeal Board which ultimately invalidated a patent covering the drug's primary indication. Preston Ratliff and Joseph O'Malley obtained a noteworthy win for Sumitomo Dainippon Pharma and Sunovion at the Federal Circuit, which affirmed a district court decision preventing multiple generic challengers from marketing their own versions of the client's billion-dollar drug Latuda.
Articles
Now accepting firm surveys and partner interviews